Loading patent…
AssigneesBaxter Healthcare S.A., Baxter Internationsl Inc.
InventorsKatalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
Estimating the term…
The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
1-6. (canceled)
A method for testing the effectiveness of a treatment for thrombotic thrombocytopenic purpura (TTP) in a subject comprising measuring a level of von Willebrand Factor (VWF) cleavage fragments in a blood sample from the subject before and after the treatment, wherein a decrease in amount of ultra-large multimer forms of VWF with a reduced triplet structure after the treatment indicates that the treatment is effective in increasing a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity or concentration in the subject.
(canceled)
20-21. (canceled)
The method of claim 21, wherein the subject is human.
23-24. (canceled)
27-42. (canceled)
Dependencies are inferred from the claim text.